A First-in-Human Single and Multiple Ascending Dose Study of MT-501

Inclusion Criteria:

1. Male or female (of non-childbearing potential only) between 19 and 55 years of ageinclusive, at the time of signing informed consent.

2. Females must be of non-childbearing potential and must have undergone sterilizationprocedures, and have official documentation, at least 6 months prior to the firstdose.

3. Male subjects must use highly effective forms of contraception during sexualintercourse with female partners of childbearing potential. A non-vasectomized, malesubject must agree to use a condom with a chemical barrier method.

4. Continuous non-smoker who has not used tobacco or nicotine-containing products forat least 3 months prior to the first dose of drug.

5. Good general health.

6. Able to provide written informed consent and understand and comply with therequirements of the study.

Exclusion Criteria:

1. History or presence of any clinically significant organ system disease.

2. Abnormal laboratory assessments, physical exam of ECG outside the normal range thatis judged by the Investigator to be clinically significant.

3. History of alcohol or drug abuse within the past 24 months.

4. Current use or history of regular tobacco, or nicotine-containing products within 3months prior to screening.

5. Administration or use of any investigational drug or device within 30 days precedingthe first does of study drug administration.